KRAS Biomarkers
KRAS, MSI Testing Associated With Better Outcomes for Colorectal Cancer Patients, Study Finds
The analysis of more than 40,000 patients' data also showed that those living in the rural South and getting treatment at a community practice were less likely to be tested.
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
FDA Approves Entrogen's RAS Mutation Detection Kit as CDx for Vectibix
The test, intended for use with Amgen's Vectibix, detects KRAS and NRAS exon 2, 3, and 4 mutations in colorectal cancer patients.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.